Cancer Neoantigens

Cancer neoantigens are novel peptides presented by cancer cells that arise from tumor-specific mutations. Unlike normal cellular proteins, these neoantigens are recognized as foreign by the immune system, making them promising targets for cancer immunotherapy. Neoantigen-based therapies, such as personalized cancer vaccines and adoptive T-cell transfer, aim to harness the body’s immune response to selectively attack tumor cells while sparing healthy tissue. Recent advances in genomics and bioinformatics have accelerated the identification and validation of neoantigens, paving the way for highly individualized treatments. These therapies hold potential for improved efficacy and reduced toxicity compared to traditional cancer treatments, marking a significant advancement in personalized oncology.